Form 8-K - Current report:
SEC Accession No. 0001193805-21-000002
Filing Date
2021-01-04
Accepted
2021-01-04 06:03:27
Documents
15
Period of Report
2020-12-29
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 e620187_8k-immunic.htm   iXBRL 8-K 26328
2 e620187_ex5-1.htm EX-5.1 7715
3 e620187_ex10-1.htm EX-10.1 269269
7 GRAPHIC image_001.jpg GRAPHIC 2179
  Complete submission text file 0001193805-21-000002.txt   557487

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA imux-20201229.xsd EX-101.SCH 3223
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE imux-20201229_lab.xml EX-101.LAB 34592
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE imux-20201229_pre.xml EX-101.PRE 22735
8 EXTRACTED XBRL INSTANCE DOCUMENT e620187_8k-immunic_htm.xml XML 3601
Mailing Address AM KLOPFERSPITZ 19 MARTINSRIED 2M 82152
Business Address AM KLOPFERSPITZ 19 MARTINSRIED 2M 82152 49 89 250079460
IMMUNIC, INC. (Filer) CIK: 0001280776 (see all company filings)

EIN.: 562358443 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36201 | Film No.: 21500029
SIC: 2834 Pharmaceutical Preparations